These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36526397)

  • 1. Erratum to: Jones, CU; Pugh, SL; Sandler, HM; Chetner, MP; Amin, MB; Bruner, DW; Zietman, AL; Den, RB; Leibenhaut, MH; Longo, JM; Bahary, JP; Rosenthal, SA; Souhami, L; Michalski, JM; Hartford, AC; Amin, PP; Roach, M 3rd; Yee, D; Efstathiou, JA; Rodgers, JP; Feng, FY; Shipley, WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys 2022;112:294-303. doi: 10.1016/j.ijrobp.2021.08.031.
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):265. PubMed ID: 36526397
    [No Abstract]   [Full Text] [Related]  

  • 2. Erratum to: Caudell JJ, Torres-Saavedra PA, Rosenthal DI, Axelrod RS, et al. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2023;116:533-543.
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):774-776. PubMed ID: 37578414
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on "Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer." Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Harvard Radiation Oncology Program, Boston, MA.: Cancer 2013;119(9):1729-35. doi: 10.1002/cncr.27956. [Epub 2013 Feb 22].
    Gottschalk A
    Urol Oncol; 2014 Apr; 32(3):373-4. PubMed ID: 24679463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum to: Tward, J; Lenz, L; Flake II, DD; Rajamani, S; Yonover, P; Olsson, C; Kapoor, DA; Mantz, C; Liauw, SL; Antic, T; Fabrizio, M; Salzstein, D; Shore, N; Albertson, D; Henderson, J; Lee, SP; Gay, HA; Michalski, J; Hung, A; Raben, D; Garraway, I; Lewis, MS; Nguyen, PL; Marshall, DT; Brawer, MK; Stone, S; Cohen, T. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol Biol Phys 2022;113:66-76. doi.org/10.1016/j.ijrobp.2021.09.034.
    Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):543. PubMed ID: 36621237
    [No Abstract]   [Full Text] [Related]  

  • 5. Erratum to: Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation Dose-Volume Effects in Radiation-Induced Rectal Injury. Int J Radiat Oncol Biol Phys 2010;76:S123-S129.
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1185. PubMed ID: 31327421
    [No Abstract]   [Full Text] [Related]  

  • 6. In regard to Purdy JA, Michalski JM. Does the evidence support the enthusiasm over 3D conformal radiation therapy and dose escalation in the treatment of prostate cancer? Int J Radiat Oncol Biol Phys 2001;51:867-870.
    Levitt SH; Khan FM
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):1085; author reply 1085-6. PubMed ID: 12095577
    [No Abstract]   [Full Text] [Related]  

  • 7. Erratum to: Trifiletti DM, Ballman KV, Brown PD, Anderson SK, Carrero XW, Cerhan JH, Whitton AC, Greenspoon J, Parney IF, Laack NN, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG II, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D. Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). Int J Radiat Oncol Biol Phys 2020;106:255-260.
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):1111. PubMed ID: 32171455
    [No Abstract]   [Full Text] [Related]  

  • 8. Erratum to: van der Velden JM, Peters M, Verlaan J-J, Versteeg AL, Zhang L, Tsao M, Danjoux C, Barnes E, van Vulpen M, Chow E, Verkooijen HM. Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases. Int J Radiat Oncol Biol Phys 2017;99:859-866.
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1186. PubMed ID: 31327423
    [No Abstract]   [Full Text] [Related]  

  • 9. In regards to Roach et al. defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference (Int J Radiat Oncol Biol Phys 2006;65:965-974).
    Cheung R
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1274; author reply 1274-5. PubMed ID: 17145548
    [No Abstract]   [Full Text] [Related]  

  • 10. Erratum to: Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2018;101:309-315.
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):226. PubMed ID: 30967236
    [No Abstract]   [Full Text] [Related]  

  • 11. Erratum to: Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu XD, Reis I, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy. Int J Radiat Oncol Biol Phys 2020;107:305-315.
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):328. PubMed ID: 32819616
    [No Abstract]   [Full Text] [Related]  

  • 12. Erratum to: Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: Consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 2016;95:632-646.
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):486. PubMed ID: 27598818
    [No Abstract]   [Full Text] [Related]  

  • 13. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions: in regard to Lawton et al. (Int J Radiat Oncol Biol Phys 2007;69:646-655.).
    Millar J; Boyd R; Sutherland J
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):316; author reply 316. PubMed ID: 18406900
    [No Abstract]   [Full Text] [Related]  

  • 14. Erratum to: Nguyen PL. Rethinking the Balance of Risk and Benefit of Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2016;94:975-977.
    Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1549. PubMed ID: 27479731
    [No Abstract]   [Full Text] [Related]  

  • 15. In reply to Furweger et al. (Int J Radiat Oncol Biol Phys DOI: 10.1016/j.ijrobp.2009.11.030).
    Ma L; Sahgal A; Larson D
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1324; author reply 1324. PubMed ID: 22385727
    [No Abstract]   [Full Text] [Related]  

  • 16. Erratum to: Hindley A, Zain Z, Wood L, et al. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. Int J Radiat Oncol Biol Phys 2014;90:748-755.
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):882. PubMed ID: 25752410
    [No Abstract]   [Full Text] [Related]  

  • 17. Low or high fractionation dose B-radiotherapy for pterygium? A randomized clinical trial: in regard to Viani GA et al. (Int J Radiat Oncol Biol Phys 2010;10.1016/j.ijrobp.2010.11.017).
    Ali AM; Thariat J
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):493; author reply 493. PubMed ID: 22182720
    [No Abstract]   [Full Text] [Related]  

  • 18. What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
    Nieder C
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):640-1; author reply 641. PubMed ID: 17869682
    [No Abstract]   [Full Text] [Related]  

  • 19. In regard to Dr. Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860).
    Kondziolka D; Lunsford LD; Flickinger JC
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):614-5; author reply 615-6. PubMed ID: 15890607
    [No Abstract]   [Full Text] [Related]  

  • 20. Erratum to: Ho AY, Olm-Shipman M, Zhang Z, et al. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. Int J Radiat Oncol Biol Phys 2018;101;325-333.
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):231. PubMed ID: 30102200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.